"The Novartis team was the fastest we've met in terms of taking the deal from conception to completion. We also appreciated the transparency of the process - it was always clear to us what were the pending steps and the key decision milestones along the route to closure. The team was well organised and reliable and communication was always punctual. These are the things that biotech is always looking for in a negotiation with big pharma, but encounters all too rarely."
 

Simon Moroney, CEO, MorphoSys AG
 

"The Novartis Strategic Alliances Group is a pleasure to work with. The group's experience, professionalism, creativity and genuine desire to find mutually acceptable solutions during and after the negotiating process fosters a cooperative atmosphere that results in positive contract outcomes and rewarding partnerships.  Novartis' practices should be reviewed by anyone in the industry looking to benchmark their alliance/partnering capabilities."
 

J. William Freytag, President and CEO, Myogen, Inc.
 

"Throughout the SCD1 deal negotiations, Xenon was impressed by the professionalism, committment and diligence shown by Novartis and its Strategic Alliance team. The outcome to the negotiation process is that both companies feel they have a fair deal. This is fundamental to a great partnership."
 

Simon N. Pimstone, President and CEO, Xenon Pharmaceuticals, Inc.
 

"We share the Novartis vision of developing better medicines by understanding the molecular basis for disease, and are impressed by the combination of science and technologies NIBRI is assembling from its own teams and from outside partners. We are delighted to be part of this effort. In both the setting up of the relationship (the negotiation of the contractual terms and the design of the research plan), and in its contribution to the management of the collaboration, Novartis continues to earn our respect for its professional approach."
 

Tim Edwards, CEO, Cellzome AG